Siemens Healthineers Awarded up to $83 Million for Photon Flash Therapy

The U.S. Advanced Research Projects Agency for Health (ARPA-H) has awarded Varian, a Siemens Healthineers business, up to $60 million over five years to advance photon Flash therapy. This experimental radiotherapy approach delivers treatment at ultra-high dose rates, more than 100 times faster than current technologies. To support this development, Siemens Healthineers will contribute an additional $23 million in cost-sharing, bringing the total combined commitment for photon FLASH-RT development to $83 million.

Accelerating Scalable Flash Radiotherapy
While previous Flash radiotherapy research has primarily utilized proton and electron beam platforms, these technologies face significant scalability and access constraints. By focusing on photon beams, which remain the standard of care for over 50% of cancer patients, the company aims to create a treatment option that is both cost-effective and compatible with existing clinical infrastructure.

Clinical Workflow and Global Access
The initiative seeks to integrate photon Flash therapy into established clinical workflows by utilizing the extensive installed base of C-arm linear accelerators. This strategy is intended to speed up adoption and enable broader access to advanced innovations for communities worldwide. Arthur Kaindl, head of Varian at Siemens Healthineers, noted that building on this existing technology base is central to the goal of bringing precise and efficient cancer treatment within reach of more patients globally.

Recognizing Radiotherapy Innovation
This award marks a significant milestone as one of the first major federal investments of its kind in radiation oncology. Leaders from the American Society for Radiotherapy and Oncology (ASTRO) and the European Society for Radiotherapy and Oncology (ESTRO) highlighted that this funding addresses a traditional gap in global cancer research. The investment is expected to drive the development of improved technologies and more efficient treatment methodologies for the oncology community.

Additional Context
The development of Flash radiotherapy represents a potential paradigm shift in oncology by leveraging the "Flash effect," where ultra-high dose rates appear to significantly reduce damage to healthy tissue while maintaining effective tumor control. This allows clinicians to potentially treat aggressive or deep-seated tumors that were previously considered too risky due to the proximity of critical organs.

Technically, the move toward photon-based Flash is significant because photon-emitting linear accelerators (LINACs) are far more common in hospitals than proton therapy centers. Integrating Flash capabilities into C-arm LINACs requires sophisticated upgrades to the power and control systems to deliver the necessary dose in a fraction of a second. Successfully transitioning this technology from an experimental modality to a global standard of care would effectively modernize the world’s existing radiotherapy infrastructure without requiring the massive capital expenditure associated with building new proton or electron-beam facilities.

Edited by Romila DSilva, Induportals Editor, with AI assistance.